Actos
Actos is a pharmaceutical drug with 7 clinical trials. Currently 1 active trials ongoing. Historical success rate of 83.3%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
83.3%
5 of 6 finished
16.7%
1 ended early
1
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Prevention of Progression of Prediabetes, Obesity and CV Risk
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.
A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Clinical Trials (7)
Prevention of Progression of Prediabetes, Obesity and CV Risk
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.
A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7